US EditionJohnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
- Johnson & Johnson announced Phase 1 first-in-human results for pasritamig, a bispecific T-cell-engaging antibody, on June 1, 2025, in Chicago.
- The research focused on an advanced form of prostate cancer characterized by disease progression despite androgen deprivation, where patients typically have few remaining treatment alternatives, including chemotherapy and hormone-based therapies.
- The trial evaluated 174 patients aged 36 to 89 who had received an average of four prior therapies, demonstrating pasritamig's potential to activate T-cells against KLK2-expressing tumor cells with outpatient dosing.
- Among 33 patients treated at the recommended phase 2 dose of 3.5mg every six weeks, 42.4% achieved a 50% or greater PSA reduction and median radiographic progression-free survival was 7.9 months.
- These encouraging results suggest pasritamig is well-tolerated with manageable side effects and supports further development as a novel, targeted therapy for difficult-to-treat mCRPC patients.
20 Articles
20 Articles
Life beyond lung cancer: Johnson & Johnson’s Breathtaking vision at ASCO 2025
Discover Johnson & Johnson’s groundbreaking Breathtaking campaign, unveiled at ASCO 2025 in Chicago. Watch the exclusive interview with Biljana Naumovic for insights into J&J’s patient-first approach and the Oncology Care Index.
Journal Gazette & Times-Courier
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting
ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug
Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer (mCRPC).The post ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug appeared first on Clinical Trials Arena.
ASCO25: AI Test Shown To Aid In Prostate Cancer Treatment Planning - Data Intelligence
In the UK, around 50,000 men are diagnosed with prostate cancer annually, according to Cancer Research UK. Image credit: Antonio Marca via Shutterstock. New research has demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. Abiraterone (Zytiga) is an androgen deprivation therapy (ADT) used in men wit…
Coverage Details
Bias Distribution
- 79% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
